The majority of individuals suffering from a neurocognitive disorder face associated psychiatric disturbances at some point in the course of their disease. Timely recognition of the presence of depression, anxiety, agitation, psychosis, and apathy within the context of a neurocognitive disorder is essential. While the treatment of these disturbances may follow the form of that for individuals without cognitive impairment, it often involves unique approaches in order to optimize outcomes. This session will review key considerations for the selection and dosing of psychotropic medications for major psychiatric illnesses associated with neurocognitive disorders. Strategies for minimizing adverse effects of treatment, particularly in elderly individuals, will also be discussed.
